Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Person › Details

John Harris (OBN (UK) Ltd.)

Harris, John G. (OBN 201604 CEO)


Organisation Organisation OBN (UK) Ltd.
Products Product business development (state/region)
  Product 2 BIOTECH

OBN (UK) Ltd.. (4/28/16). "Press Release: Elasmogen Winner of the Perfect Pitch at the 2016 BioTrinity Conference in London". London.

OBN - the membership organisation supporting the UK’s emerging life sciences companies, announces today that the winner of the Perfect Pitch Competition, taking place at BioTrinity its annual conference in London for the first time on 27th April 2016, was Elasmogen Ltd. This fast-paced, interactive and lively session saw nine emerging UK R&D companies pitch in front of a panel of seasoned investors including:

> Kate Bingham, Managing Partner, SV Life Sciences

> Maina Bhaman, Director of Healthcare Investments, Imperial Innovations

> David Phillips, Partner, SR One

> Graeme Martin, President & CEO, Takeda Ventures Inc.

> Naveed Siddiqi, Partner, EdRIP

> Detlev Mennerich, Investment Manager, Boehringer Ingelheim Ventures

The judges selected Elasmogen to win the coveted Perfect Pitch winner’s certificate which also included a 30-munite masterclass with the host and panel members. Dr Caroline Barelle, CEO of Elasmogen, presented in a three minute pitch on their proprietary soloMER™ technology that exploits the power of biologics as drugs but in a small (1/12 the size of an antibody), stable format that enables site specific delivery through complex and challenging environments like the eye and gut

Kate Bingham, Managing Partner at SV Life Sciences and Chair of the Perfect Pitch session, said “Elasmogen was selected based on its confidence, style and pitch. All the judges were very impressed by Caroline as well as the other contestants. The passion and energy they all brought to communicating their vision for their business was only surpassed by the quality of their science. Hopefully the relationships they have made during BioTrinity will help them successfully advance their products and innovations.”

John Harris, CEO of OBN, commented, “We applaud the talented individuals that competed in this challenge and the high quality of their pitches. This competition, the first organised at BioTrinity, aims to put these emerging UK life sciences companies on the right track to move their innovation forward.”

The ten companies, that presented their innovation included:
Alfacyte, BeamLine Diagnostics, Curileum Discovery, DJS Antibodies, Elasmogen, NALIA Systems, NeRRe Therapeutics, Ryboquin Company and Somanautix

The End


John Harris, CEO, OBN
Tel: +44 (0)7881 675990

Citigate Dewe Rogerson
Sylvie Berrebi, Katja Stout
Tel: +44 (0)20 7638 9571

About OBN

OBN is the Membership organisation supporting and bringing together the UK’s innovative life sciences companies, corporate partners and investors. Our 400-plus member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland and benefit from our networking, partnering, purchasing, advising and advocacy activities. OBN is best known for its delivery of BioTrinity (the 11th edition is on 8-10 May 2017) Europe’s leading life sciences investment and biopartnering conference.

Further information about OBN’s tailored networking and partnering events, purchasing consortium, advice, consultancy services and advocacy activities is available on OBN’s website

Record changed: 2020-06-26


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for John Harris

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top